Asthma and lower airway disease
Treatment adherence in asthmatic patients: The last frontier?

https://doi.org/10.1016/j.jaci.2014.08.004Get rights and content

References (12)

There are more references available in the full text version of this article.

Disclosure of potential conflict of interest: E. D. Bateman's institution has received funding from Boehringer Ingelheim, AstraZeneca, Almirall, Novartis, Merck, Takeda, Actelion, Aeras, Chiesi, Cephalon, Sanofi-Aventis, TEVA, and Glaxo SmithKline; he has received compensation for board membership and/or delivering lectures from AstraZeneca, Elevation Pharma, Napp Pharma, Novartis, Almirall, Forest, Merck, Takeda, GlaxoSmithKline, Chiesi, Nycomed, and Pfizer; and he has received consultancy fees from Navigant Consulting, the IMS Consulting Group, ALK-Abelló, Hoffmann la Roche, ICON, Actelion, Aeras, and Cephalon.

View full text